Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study

Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.285916. Online ahead of print.

Abstract

Not available.